Barclays Cuts OHI Price Target to $48

Barclays has reaffirmed its Underweight rating on Omega Healthcare Investors, Inc. with a new price target of $48.00, a 5.26% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 2:26 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Barclays cut its price target on Omega Healthcare Investors, Inc. ($OHI) to $48 from $50 on October 13, 2026, and rates the stock "Underweight".

Since the rating, $OHI is up 0.9% to date (from the $45.22 close on Oct 13, 2026).

OHI Omega Healthcare Investors, Inc.

$45.64 +6.99% year to date

Daily close · Oct 16, 2026

Key Points

On October 13, 2026, Barclays reiterated its Underweight rating on Omega Healthcare Investors, Inc. with a price target of $48.00, down from $50.00.
Barclays's $48 price target implies 5.26% upside from Omega Healthcare Investors, Inc.'s ($OHI) current $45.60 share price.
As of October 16, the stock was recently trading around $45.60, which is about 5% below Barclays' new target.
Omega Healthcare Investors, Inc. has a dividend rate of $2.72, with a payout ratio of 95.4%.

Get $OHI trade alerts by text

We text you when insiders, Congress or big funds trade $OHI. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Omega Healthcare Investors, Inc. alert may contain errors. Disclosures

Barclays has reiterated its Underweight rating on Omega Healthcare Investors, Inc. (NYSE: OHI) on October 13, 2026, adjusting its price target to $48.00 from $50.00. This reflects a shift in the firm's outlook on the stock, indicating a cautious stance amid current market conditions.

Other Institutional Activity in Omega Healthcare Investors

Several other institutional investors have also shown activity with Omega Healthcare. Blackrock Inc. increased its holdings by 1,350,415 shares, bringing its total to about 38.6 million shares worth approximately $1.76 billion. Cohen & Steers Inc. added 10,958,376 shares, ending with about 22.9 million shares valued at around $1.05 billion. Meanwhile, Vanguard Portfolio Management LLC grew its stake by 105,783 shares, holding around 27.2 million shares valued at about $1.24 billion.

Omega Healthcare Investors, Inc. Stock Down 2.3%

As of October 16, 2026, Omega Healthcare shares were trading around $45.60. This price is about 5% below Barclays' new target of $48.00. The stock has been fluctuating within a range that suggests cautious investor sentiment, particularly in the healthcare REIT sector.

12-month forecast

$OHI price target

Omega Healthcare Investors, Inc. daily closes and this analyst's $48 target. Not advice.

Recent Earnings

In its most recent earnings report, Omega Healthcare generated a total revenue of approximately $1.26 billion over the trailing twelve months, reflecting a year-over-year revenue growth of 11.2%. The company reported an EPS of $2.81 and a net margin of 68.1%. The next earnings report is scheduled for November 3, 2026.

Insider Buying and Selling at Omega Healthcare Investors, Inc.

Recently, there has been some insider activity at Omega Healthcare. CEO C. Taylor Pickett purchased 20,000 shares at an average price of $43.14 on November 5, 2025, totaling about $862,856. Similarly, Chief Investment Officer Vikas Gupta bought 11,500 shares at an average price of $42.97 on November 6, 2025, amounting to around $494,118. In contrast, Director Lisa Egbuonu-Davis sold 2,500 shares at $40.16 on August 8, 2025, with a total value of about $100,394.

Analysts Set New Price Targets

On October 13, 2026, Barclays maintained its Underweight rating for Omega Healthcare Investors with a new price target of $48.00, down from $50.00. This follows a similar stance by Mizuho, which maintained a Neutral rating with a target of $46.00, and Wells Fargo, which upheld an Equal-Weight rating at a target of $48.00. Meanwhile, UBS also maintained a Buy rating, adjusting its target to $52.00.

About Omega Healthcare Investors

Omega Healthcare Investors, Inc. is a real estate investment trust (REIT) focusing on the long-term healthcare sector, mainly investing in skilled nursing and assisted living facilities. The firm operates a diverse portfolio of assets under a triple-net lease structure across the U.S., UK, and Canada. The company is headquartered in Hunt Valley, Maryland.

Bottom Line

Investors should keep an eye on Omega Healthcare as it approaches its next earnings date on November 3, 2026. The stock's current trading position relative to Barclays' price target suggests ongoing caution in the market. Further analyst ratings and institutional activities may provide more insights into the stock's direction.